|
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News Archive - June 2025
Biktarvy found effective in treating people whose injectable HIV regimens failed
JUNE 19, 2025 - CATIE NEWS - Canadian AIDS Treatment Information Exchange (CATIE) - Long-acting injectable HIV treatment is highly effective, but may not work for everyone
Ottawa researchers explored alternatives for five patients whose long-acting treatment failed
In all five cases, a switch to an oral Biktarvy regimen effectively suppressed HIV
HIV treatment (antiretroviral therapy; ART) is highly effective when used as directed. A key goal of ART is to suppress HIV and keep it suppressed. This allows the immune system to largely repair itself. The power of ART is so transformative that researchers increasingly project that many ART users will live well into their senior years.
FDA Approves Yeztugo for HIV PrEP Lasting 6 Months
JUNE 18, 2025 - By IDSE News Staf - Infectious Disease Special Edition (IDSE) - The FDA approved lenacapavir (Yeztugo, Gilead Sciences), an injectable HIV-1 capsid inhibitor, to be used as pre-exposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV in adults and adolescents weighing at least 35 kg, making it the first and only twice-yearly option for Americans who need or want PrEP.
Data show that almost 100% of participants who received lenacapavir in the phase 3 PURPOSE 1 and PURPOSE 2 trials remained HIV-negative. These trials supported the FDA’s approval.
| 
